Literature DB >> 16799034

Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.

Luciano Quaranta1, Federico Gandolfo, Raffaele Turano, Federico Rovida, Teodoro Pizzolante, Andrea Musig, Enrico Gandolfo.   

Abstract

PURPOSE: To compare the short-term effects of timolol 0.5%, brimonidine 0.2%, dorzolamide 2%, and latanoprost 0.005% on intraocular pressure (IOP), blood pressure (BP), and diastolic ocular perfusion pressure (DOPP), calculated as the difference between the diastolic blood pressure (DBP) and IOP.
METHODS: According to a 4 x 4 Latin squares design for repeated measures, 27 untreated patients and patients with newly diagnosed primary open-angle glaucoma (POAG) were treated with timolol 0.5% at 8 AM and 8 PM; brimonidine 0.2% at 8 AM and 8 PM; dorzolamide 2% at 8 AM, 2 PM, and 8 PM; and latanoprost 0.005% at 8 PM. The duration of each treatment course was 6-weeks, with a 4-week washout between each treatment. IOP and BP were measured at baseline and at the end of each treatment period. IOP was measured every 2 hours throughout a 24-hour period. Sitting IOP was measured from 8 AM to 10 PM by Goldmann applanation tonometry. Supine IOP was assessed from 12 to 6 AM by means of a handheld electronic tonometer (TonoPen XL; Mentor, Norwell, MA). BP monitoring was performed by means of an automated portable device (TM-2430; A & D Co., Saitama, Japan).
RESULTS: All the drugs tested decreased the IOP significantly at all time points in comparison with baseline pressure. The mean 24-hour IOP after latanoprost administration (16.62+/-0.98 mm Hg) was significantly lower than that after timolol, brimonidine, or dorzolamide (P=0.0001). During the 24-hour period, brimonidine induced a significant decrease in systolic BP (SBP) and DBP at all time points when compared with baseline measurements and with those after administration of the other drugs (P<0.0001). Timolol caused a significant decrease in DBP and SBP at all the 24-hour time points when compared with the baseline and with the dorzolamide- and latanoprost-induced changes (P<0.0001). The mean 24-hour DOPPs were 50.7+/-5.9 mm Hg at baseline, 53+/-5.5 mm Hg with timolol, 46.2+/-5.4 mm Hg with brimonidine, 55.9+/-4.6 mm Hg with dorzolamide, and 56.4+/-4.9 mm Hg with latanoprost. Brimonidine induced a significant decrease in the mean 24-hour DOPP compared with that at baseline (P<0.0001), whereas dorzolamide and latanoprost induced a significant increase (P<0.0001).
CONCLUSIONS: Latanoprost seemed to induce a uniform reduction in IOP during the 24-hour period, although timolol was as effective as latanoprost during the daytime, and dorzolamide are as effective as latanoprost at night. SBP and DBP were significantly decreased by either timolol or brimonidine. In this study of patients with newly diagnosed POAG, only dorzolamide and latanoprost significantly increased mean 24-hour DOPP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799034     DOI: 10.1167/iovs.05-1253

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  42 in total

1.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

2.  Clinical evidence for neuroprotection in glaucoma.

Authors:  M Francesca Cordeiro; Leonard A Levin
Journal:  Am J Ophthalmol       Date:  2011-11       Impact factor: 5.258

3.  The Diurnal and Nocturnal Effects of Pilocarpine on Intraocular Pressure in Patients Receiving Prostaglandin Analog Monotherapy.

Authors:  Leonard K Seibold; Brandie D Wagner; Anne M Lynch; Malik Y Kahook
Journal:  J Ocul Pharmacol Ther       Date:  2018-09-07       Impact factor: 2.671

4.  Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.

Authors:  Chandrasekar Durairaj
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

5.  Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action.

Authors:  Matt H Oltmanns; Sandeep S Samudre; Ivan G Castillo; Alireza Hosseini; Aron H Lichtman; Robert C Allen; Frank A Lattanzio; Patricia B Williams
Journal:  J Ocul Pharmacol Ther       Date:  2008-02       Impact factor: 2.671

6.  Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.

Authors:  Luciano Quaranta; Raffaele Turano; Teodoro Pizzolante
Journal:  Clin Ophthalmol       Date:  2007-06

7.  Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma.

Authors:  Yuya Nomura; Shunsuke Nakakura; Mitsuyasu Moriwaki; Yasuhiro Takahashi; Kunihiko Shiraki
Journal:  Clin Ophthalmol       Date:  2010-07-30

8.  The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma.

Authors:  Andrzej Stankiewicz; Joanna Wierzbowska; Anna Siemiatkowska; Beata Fuksinska; Jacek Robaszkiewicz; Arkadiusz Zegadlo; Rita Ehrlich; Brent Siesky; Alon Harris
Journal:  Br J Ophthalmol       Date:  2010-06-16       Impact factor: 4.638

9.  Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.

Authors:  Chandrasekar Durairaj; Jie Shen; Madhu Cherukury
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

10.  Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma.

Authors:  Ciro Costagliola; Francesco Parmeggiani; Gianni Virgili; Giuseppe Lamberti; Carlo Incorvaia; Paolo Perri; Claudio Campa; Adolfo Sebastiani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-11-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.